Dyadic International, Inc. (DYAI)
Stock Price:
$7.45 USD
-0.21 (-2.74%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
204.74M |
| Revenue (ttm) |
1.73M |
| Net Income (ttm) |
-8.30M |
| Shares Out |
27.48M |
| EPS (ttm) |
-0.30 |
| PE Ratio |
n/a |
| Forward PE |
20.37 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$7.45 |
| Previous Close |
$7.66 |
| Change ($) |
-0.21 |
| Change (%) |
-2.74% |
| Day's Open |
7.50 |
| Day's Range |
7.25 - 7.50 |
| Day's Volume |
86,997 |
| 52-Week Range |
2.51 - 10.98 |
More Stats
| Market Cap |
204.74M |
| Enterprise Value |
172.91M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.48M |
| Float |
19.22M |
| EPS (basic) |
-0.31 |
| EPS (diluted) |
-0.30 |
| FCF / Share |
-0.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.29M |
| Short Ratio |
11.53 |
| Short % of Float |
6.71% |
| Beta |
0.35 |
| PE Ratio |
n/a |
| Forward PE |
20.37 |
| P/FCF Ratio |
n/a |
| PS Ratio |
118.53 |
| PB Ratio |
5.93 |
| Revenue |
1.73M |
| Operating Income |
-9.00M |
| Net Income |
-8.30M |
| Free Cash Flow |
-6.85M |
| Net Cash |
31.83M |
| Net Cash / Share |
1.16 |
| Gross Margin |
12.82% |
| Operating Margin |
-521.10% |
| Profit Margin |
-480.70% |
| FCF Margin |
-396.33% |
| ROA |
-15.25% |
| ROE |
-23.48% |
| ROIC |
-29.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$11.00*
(47.65% upside)
Low
10.0
Current: $7.45
High
12.0
Target: 11.00
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 1.68 | 1.30 | 0.76 | 0.59 |
| Revenue Growth | 29.77% | 70.81% | 27.92% | - |
| Gross Profit | 0.22 | 0.27 | 0.08 | 0.08 |
| Operating Income | -9.25 | -7.57 | -7.38 | -5.81 |
| Net Income | -8.31 | -5.69 | -2.14 | -3.61 |
| Shares Outstanding | 27.00 | 27.67 | 28.92 | 36.54 |
| Earnings Per Share | -0.31 | -0.21 | -0.07 | -0.10 |
| Operating Cash Flow | -5.78 | -4.41 | -1.69 | -6.03 |
| Free Cash Flow | -5.78 | -4.41 | -1.69 | -6.03 |
| Cash & Equivalents | 34.22 | 41.20 | 47.69 | 48.94 |
| Net Cash / Debt | 34.22 | 41.20 | 47.69 | 48.94 |
| Assets | 37.45 | 43.30 | 50.74 | 58.70 |
| Liabilities | 1.59 | 0.85 | 0.77 | 1.01 |
| Book Value | 35.86 | 42.45 | 49.98 | 57.69 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Dyadic International, Inc. |
| Country |
United States |
| Employees |
6 |
| CEO |
Mark A. Emalfarb |
Stock Information
| Ticker Symbol |
DYAI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DYAI |
| IPO Date |
November 5, 2004 |
Description
Dyadic International, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd., as well as with the Israel Institute for Biological Research; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; research collaboration with Sanofi-Aventis Deutschland GmbH; research and commercialization collaboration with Serum Institute of India Pvt.; and nonexclusive research collaboration with WuXi Biologics. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.